Diaceutics (LON:DXRX) Shares Down 1.4% – What’s Next?

Diaceutics PLC (LON:DXRX)’s stock price traded down 1.4% on Monday. The company traded as low as GBX 198 and last traded at GBX 200. 498,908 shares were traded during trading, an increase of 113% from the average daily volume of 233,936 shares. The stock had previously closed at GBX 202.75.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group reissued a “buy” rating and set a GBX 215 price objective on shares of Diaceutics in a research note on Tuesday. Two equities research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of GBX 215.

Diaceutics Price Performance

The company has a debt-to-equity ratio of 5.40, a quick ratio of 9.92 and a current ratio of 2.55. The business has a 50-day simple moving average of GBX 187.36 and a 200 day simple moving average of GBX 160.73. The firm has a market cap of £156.35 million, a P/E ratio of -575.00 and a beta of 0.88.

Diaceutics (LON:DXRX) last issued its quarterly earnings data on Tuesday, September 22nd. The company reported GBX (3.27) earnings per share for the quarter. Diaceutics had a negative return on equity of 0.68% and a negative net margin of 0.66%. On average, analysts anticipate that Diaceutics PLC will post 1.01 earnings per share for the current fiscal year.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.